Enfuvirtide (T-20) resistance-related mutations in HIV Type 1 subtypes B, C, and F isolates from brazilian patients failing HAART

AIDS Research and Human Retroviruses

Volumn 25, Issue 2, 2009, Pages 193-198

  Oliveira, A C A ^a   Martins, A N ^a   Pires, A F N P C ^a   Arruda, M B ^a   Tanuri, A ^a   Pereira, H S ^a,b   Brindeiro, R M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMINO ACID; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MUTATION; PLASMA; PREVALENCE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; YOUNG ADULT;

EID: 60849084600     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0160     Document Type: Article

References (28)

1. Moore JP and Doms RW: The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA 2003;100(19):10598-10602.
2. Weissennhorn W, Dessen A, Harrison SC, Skehel JJ, and Wiley DC: Atomic structure of the ectodomains from HIV-1 gp41. Nature 1997;387:426-430.
3. Chan D, Fass D, Berger J, and Kim P: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
4. Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardie're J, Pacanowski J, Meynard JL, Hance AJ, Clavel F, and Mammano F: Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006;80(17):8807-8819.
5. Deeks SG: Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003;362(9400):2002-2011.
6. Poveda E, Briz V, and Soriano V: Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005;7(3):139-147.
7. Si-Mohamed A, Piketty C, Tisserand P, LeGoff J, Weiss L, Charpentier C, Kazatchkine M D, and Be'lec L: Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J Acquir Immune Defic Syndr 2006;44(1):1-5.
8. Carmona R, Pérez-Alvarez L, Muñoz M, et al.: Natural resistance-associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 2005;32:248-253.
9. Weiss CD: HIV-1 gp41: Mediator of fusion and target for inhibition. AIDS Rev 2003;5(4):214-221.
10. Rimsky LT, Shugars DC, and Matthews TJ: Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998;72(2):986-993.
11. Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, Faudon JL, Clavel F, Schapiro J, and Soriano V: Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 2004;74(1):21-28.
12. Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, and Doms RW: Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol 2007;81(7):3240-3250.
13. Derdeyn CA, Decker JM, Sfakianos JN, et al.: Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000;74(18):8358-8367.
14. Poveda E, Rodes B, Toro C, et al.: Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 2002;16:1959-1961.
15. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, and Kappes JC: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46(6):1896-1905.
16. Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, and Greenberg ML: Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 2005;79(19):12447- 12454.
17. Baldwin CE and Berkhout B: Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein. Retrovirology 2006;3:84.
18. Kumar S, Tamura K, and Nei M: MEGA 3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 2004;5:150-163.
19. de-Oliveira T,DeforcheK, Cassol S, SalminemM, ParaskevisD, Seebregts C, Snoeck J, van Rensburg EJ,Wensing AMJ, van de Vijver DA, Boucher CA, Camacho R, and Vandamme AM: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinfomatics 2005;21(19):3797-3800.
20. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, and Ray SC: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73(1):152-160.
21. Thompson JD, Higgins DG, and Gibson TJ: CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
22. Peeters M: The genetic variability of HIV-1 and its implications. Transfus Clin Biol 2001;8:222-225.
23. Brindeiro RM, Diaz RS, Sabino EC, Morgado MG, Pires IL, Brigido L, Dantas MC, Barreira D, Teixeira PR, and Tanuri A: Brazilian network for HIV drug resistance surveillance (HIV-BResNet): A survey of chronically infected individuals. AIDS 2003;17(7):1063-1069.
24. Sa-Ferreira JA, Brindeiro PA, Chequer-Fernandez S, Tanuri A, and Morgado MG: Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naive Brazilian blood donors. Transfusion 2007;47(1):97-102.
25. Soares EA, Santos RP, Pellegrini JA, Sprinz E, Tanuri A, and Soares MA: Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J Acquir Immune Defic Syndr 2003;34:520-526.
26. Heil ML, Decker JM, Sfakianos JN, et al.: Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 2004;78(14):7582-7589.
27. Greenberg M and Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-340.
28. Cabrera C, Marfila S, García E, et al.: Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 2006;20:2075-2080.